Recent share performance and business mix

AptarGroup (ATR) has come onto investors’ radar after a recent share pullback, with the stock down about 3% over the past day and roughly 6% over the past month.

Over the past 3 months, the stock has fallen about 20%, contributing to a year to date decline of roughly 8% and a 1 year total return decline of about 27%.

Against that share performance, the company reports annual revenue of about US$3.9b and net income of roughly US$386.7m. Both revenue and net income show single digit annual growth rates.

With the share price down about 20% over the past 90 days and the 1 year total shareholder return also in decline, recent momentum looks weak compared with the modestly positive 3 year total shareholder return.

If you are weighing AptarGroup alongside other opportunities, this could be a good moment to see what else is moving and broaden your search with the 20 top founder-led companies

With AptarGroup stock down over the past year but trading at a sizeable discount to some analyst targets and intrinsic value estimates, are you looking at an overlooked opportunity here, or is the market already factoring in future growth?

Most Popular Narrative: 30.4% Undervalued

Simply Wall St's most followed narrative places AptarGroup's fair value at about $161.43 per share, versus the last close at $112.38. This frames a sizeable valuation gap for investors to assess.

The rapid expansion of AptarGroup's proprietary drug delivery systems, particularly in injectables for biologics, GLP-1, and central nervous system therapies, positions the company to benefit from rising global healthcare needs and an aging population. These high-value platforms support future revenue growth and margin expansion.

Curious what kind of revenue path and profit margin profile have to line up for that valuation gap to make sense? The narrative leans on steady top line progress, a measured margin reset, and a richer future earnings multiple that is higher than current industry levels. All of this is stitched together with a specific discount rate and buyback assumptions that meaningfully shape the fair value math.

Result: Fair Value of $161.43 (UNDERVALUED)

However, this depends on legal costs tied to intellectual property disputes and uncertain demand for emergency medicine delivery systems not cutting deeper into margins and growth expectations.

Another way of looking at valuation

While the SWS DCF model suggests AptarGroup is trading at a large discount to an estimated future cash flow value of about $216.29, the current P/E of 18.5x is slightly above both the estimated fair ratio of 18.3x and packaging peers at 14.8x to 15.5x. This raises the question of whether the market is already pricing in a lot of the good news.

Next Steps

With the story split between risks that could weigh on the stock and rewards that could support sentiment, it makes sense to review the underlying data and form your own view while this valuation debate is fresh, then weigh both sides through the 5 key rewards and 2 important warning signs

Looking for more investment ideas?

If AptarGroup has you thinking harder about valuation and quality, now is the time to widen your watchlist and see what else fits your approach.

• Scan for income opportunities by checking out potential high-yield candidates in the 10 dividend fortresses
• Hunt for quality at a discount by reviewing the 47 high quality undervalued stocks that combine solid fundamentals with appealing prices.
• Spot potential future standouts early by browsing the screener containing 22 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.